VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2015 | Results of ELOQUENT-2 trial for treatment multiple myeloma

Dr Joseph Mikhael discusses the results of ELOQUENT-2, a phase 3, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter